Neoadjuvant Pembrolizumab plus Chemotherapy Versus Placebo plus Chemotherapy, Followed by Adjuvant Pembrolizumab Versus Placebo for Early-Stage Tnbc: Event-Free Survival Sensitivity and Subgroup Analyses from Keynote-522

AuthID
P-00X-FG9
30
Author(s)
Cortes, J
·
Dent, R
·
Pusztai, L
·
McArthur, H
·
Kummel, S
·
Bergh, J
·
Denkert, C
·
Park, YH
·
Hui, RN
·
[+10]·
Im, SA
·
Ahn, JH
·
Gion, M
·
Baron-Hay, S
·
Boileau, JF
·
Zhu, YL
·
Pan, W
·
Tryfonidis, K
·
Karantza, V
·
O'Shaughnessy, J
Tipo de Documento
Abstract
Year published
2022
Publicado
in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, ISSN: 1743-7555
Volume: 18, Páginas: 117-118 (2)
Indexing
Publication Identifiers
Wos: WOS:000871956500162
Source Identifiers
ISSN: 1743-7555
Export Publication Metadata
Info
At this moment we don't have any links to full text documens.
Name Order Nome   Name Order Nome   Name Order Nome
1 Schmid, P;   2 Cortes, J;   3 Dent, R;
4 Pusztai, L;   5 McArthur, H;   6 Kummel, S;
7 Bergh, J;   8 Denkert, C;   9 Park, YH;
10 Hui, RN;   11 Harbeck, N;   12 Takahashi, M;
13 Untch, M;   14 Fasching, PA;   15 Cardoso, F;
16 Andersen, J;   17 Patt, D;   18 Danso, M;
19 Ferreira, M;   20 Mouret-Reynier, MA;   21 Im, SA;
22 Ahn, JH;   23 Gion, M;   24 Baron-Hay, S;
25 Boileau, JF;   26 Zhu, YL;   27 Pan, W;
28 Tryfonidis, K;   29 Karantza, V;   30 O'Shaughnessy, J;